Summit Therapeutics Inc. [SMMT] - Convertible Preferred Issuance
Summit Therapeutics Inc. is issuing Class A Preferred Stock at a purchase price of $18,356.14 per share, raising aggregate gross proceeds of $2.0 billion, with each share convertible into 1,000 shares of Common Stock.
Why this matters
Summit Therapeutics Inc., a pharmaceutical company focused on developing innovative cancer treatments, has announced a significant strategic move through the issuance of Class A Preferred Stock. This issuance, priced at $18,356.14 per share, aims to raise $2.0 billion in aggregate gross proceeds. Each preferred share is convertible into 1,000 shares of common stock, reflecting a conversion price of $18.36 per common share, which is a premium over the current market price. The investment is part of a broader strategic collaboration with AstraZeneca, highlighting the potential of Summit's investigational PD-1/VEGF bispecific antibody, ivonescimab, and other cancer therapies.